Le Lézard
Classified in: Health
Subject: ATY

Judge's Order Sets 1,200 Xarelto Product Liability Lawsuits for Separate Jury Trials



NEW ORLEANS, March 8, 2018 /PRNewswire/ -- A federal district judge in New Orleans has ordered that 1,200 product defect lawsuits against leading prescription painkiller Xarelto be prepared for trial in federal courts across the country.

The decision by U.S. District Judge Eldon Fallon marks a significant milestone in multidistrict litigation (MDL) filed by thousands of individuals who have suffered serious medical complications after taking Xarelto.

In conjunction with his ruling to prepare 1,200 cases for remand to their original trial courts, Judge Fallon ordered the lawsuits to be selected in two groups of 600 cases. Within each group of 600 lawsuits, 200 will be selected by the Plaintiffs' Steering Committee (PSC), 200 selected by the defendants and 200 selected randomly by the court. The initial round of 600 lawsuits will be selected by April 30, and the second group will be identified by August 30. Once selected, each lawsuit will be subject to case-specific discovery. The Xarelto MDL includes a total of more than 18,000 lawsuits.

"These cases are important, and the facts need to be heard by juries in open court," said Andy Birchfield of the Beasley Allen law firm and co-lead counsel of the Plaintiffs' Steering Committee. "We are prepared to take these lawsuits to court one-by-one anywhere in the country until Xarelto's makers take the basic steps necessary to correct the known health and safety risks associated with this drug."

The lawsuits charge that Xarelto developers Bayer Healthcare (OTC: BAYRY) and Janssen Pharmaceuticals Inc., a subsidiary of Johnson & Johnson (NYSE: JNJ), downplayed Xarelto's risks of serious medical complications and aggressively marketed the drug as an alternative for warfarin in patients needing blood thinners to reduce the risk of dangerous clots. The lawsuits charge that doctors and patients were not fully informed of the risks, which have resulted in thousands of life-threatening complications.

The case is In re: Xarelto (rivaroxaban) Products Liability Litigation, case number 2:14-md-02592 in the U.S. District Court for the Eastern District of Louisiana.

Contact:
Mike Androvett
Mike@androvett.com    

Robert Tharp
Robert@androvett.com
800-559-4534

 

SOURCE Beasley Allen


These press releases may also interest you

at 13:00
Elucida Oncology, a biotechnology company developing a first-in-class nanotechnology platform, announced that researchers from Cornell University, some of whom are currently working with the company, have published a study in Nature outlining the...

at 13:00
The "Global Patient Engagement Solutions Market Analysis (2017-2023)" report has been added to ResearchAndMarkets.com's offering. The Global Patient Engagement Solutions Market size is expected to reach $32.2 billion by 2023, rising at a market...

at 13:00
LAKE TAHOE, Calif., June 20, 2018 /PRNewswire-PRWeb/ -- New mental health care app LARKR today announced that its mobile platform will now make it possible for clinicians and other mental health providers to privately support their existing clients...

at 13:00
The Canadian Life and Health Insurance Association (CLHIA) welcomes the announcement of the members of the Advisory Council on the Implementation of Pharmacare.  The Advisory Council's work is important to ensuring that all Canadians have access to...

at 12:52
ISMIE Indemnity, an excess and surplus line division of ISMIE Mutual Insurance Company, announced today that it now offers medical liability insurance products in every state in the U.S. With approval from state insurance regulators, ISMIE...

at 12:49
Canadians are proud of our publicly funded health care system, which is based on need and not on ability to pay. However, prescription drugs are not covered in a consistent way across the country, and too many Canadians cannot afford the medicines...




News published on 8 march 2018 at 16:33 and distributed by: